Overview
Tuberculosis, caused by Mycobacterium tuberculosis, is a chronic infectious disease that affects millions of people around the world. It is one of the leading causes of death globally, and current treatment regimens often involve long-term administration of multiple drugs with severe side effects. In recent years, there has been a concerted effort to discover new drugs and therapies for tuberculosis using advanced pharmaceutical science and technology. This has involved a range of innovative approaches, such as computer-aided molecular design, high-throughput screening, and structural biology. One promising avenue of research is the development of drugs that target specific components of the mycobacterial cell envelope. These components are essential for bacterial growth and survival, but are not present in mammalian cells, making them attractive targets for selective drug action. Another area of interest is the search for new drugs that target the bacterium's dormant or "persisting" forms. These forms are thought to be responsible for the long treatment durations required to cure tuberculosis, and researchers are exploring a range of approaches to target and destroy them. Finally, there is also growing interest in combining existing drugs with novel therapies to create more effective combination therapies. This approach involves identifying drugs with synergistic activity, reducing treatment times and potentially reducing the risk of drug resistance. Overall, the field of tuberculosis drug discovery is constantly evolving, with new technologies and research findings driving progress towards more effective treatments. By harnessing the power of advanced pharmaceutical science, we are getting closer to defeating this devastating disease.